Effect of Tocilizumab Use on Mortality in COVID-19 Patients Admitted to Intensive Care Unit

Basit Öğe Kaydı
dc.contributor.authorTosun, Mustafa
dc.contributor.authorÖlmez, Hasan
dc.date.accessioned2023-04-10T20:21:01Z
dc.date.available2023-04-10T20:21:01Z
dc.date.issued2022
dc.departmentRektörlük, Rektörlüğe Bağlı Birimler, Düzce Üniversitesi Dergilerien_US
dc.description.abstractAim: Coronavirus disease 2019 (COVID-19) mostly proceeds with mild respiratory symptoms, but sometimes severe pneumonia, cytokine storm, and acute respiratory distress syndrome can develop. Anti-cytokine treatments are being tried for cytokine storm. In this study, we aimed to examine the effect of tocilizumab on mortality associated with COVID-19. Material and Methods: The study included 146 patients with moderate-to-severe acute respiratory distress syndrome diagnosed with COVID-19. The patients were divided into two groups, receiving only standard treatment (ST group, n=44), and tocilizumab treatment in addition to standard treatment (TCZ group, n=102). Groups were compared in terms of demographic, clinic, and laboratory data. Also, mortality rates were determined to detect the effect of tocilizumab on mortality. Results: Overall, 36.3% (n=53) of the patients were female, 63.7% (n=93) were male, and the mean age was 69.5±14.2 years. The mortality rate was 29.4% (n=30) in the TCZ group and 52.3% (n=23) in the ST group (p=0.009). While C-reactive protein, fibrinogen, and lactate levels on admission to the intensive care unit (ICU) were similar across the groups, the TCZ group had higher ferritin levels (p=0.006). On discharge from ICU, the TCZ group had a significant decrease in C-reactive protein (p<0.001), while their ferritin levels decreased to levels in the ST group (p=0.134). The absence of tocilizumab in the treatment regimen was associated with a 2.63-fold increase in the mortality risk. Conclusion: Tocilizumab reduces the mortality in COVID-19 patients in ICU. However, further studies are warranted to better elucidate the efficacy and side effects of tocilizumab.en_US
dc.identifier.doi10.18678/dtfd.1108303
dc.identifier.endpage234en_US
dc.identifier.issn1307-671X
dc.identifier.issue3en_US
dc.identifier.startpage227en_US
dc.identifier.trdizinid1146362en_US
dc.identifier.urihttp://doi.org/10.18678/dtfd.1108303
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1146362
dc.identifier.urihttps://hdl.handle.net/20.500.12684/11522
dc.identifier.volume24en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofDüzce Tıp Fakültesi Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19;en_US
dc.subjectcytokine storm;en_US
dc.subjecttocilizumab;en_US
dc.subjectmortality;en_US
dc.subjectinterleukin 6. COVID-19en_US
dc.subjectsitokin fırtınasıen_US
dc.subjecttocilizumaben_US
dc.subjectmortaliteen_US
dc.subjectinterlökin 6en_US
dc.titleEffect of Tocilizumab Use on Mortality in COVID-19 Patients Admitted to Intensive Care Uniten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11522.pdf
Boyut:
462.21 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Düzce Tıp Fakültesi Dergisi Koleskiyonu